Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

https://clinicaltrials.gov/ct2/show/NCT03053063

First impressions: it is a long trial (240 weeks dosing), measures fibrosis stage reduction, for well compensated patients (MELD score below 12).
It seems to target a segment not covered by CNAT, ie compensated patients who do not necessarily have a High Portal Vein Pressure issue (hence they are not classified as at high risk of developing decompensation). I think was done on purpose to target a segment not currently covered by any other drugs under development, anyway top line results not earlier than 2020.